Be vigilant for diabetes triggered by checkpoint inhibitors

Sudden and irreversible diabetes triggered by immune checkpoint inhibitors is set to become more common as immunotherapy becomes the standard of care in cancer therapy, endocrinologists say. Until now fulminant islet autoimmunity that presents as diabetic ketoacidosis (DKA) has been considered a rare complication of anti-PD1 cancer therapies, but the situation is likely to change ...

Already a member?

Login to keep reading.

© 2022 the limbic